- Home
- EWTX vs SSII Comparison
EWTX vs SSII Comparison
Compare EWTX & SSII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- SSII
- Stock Information
- Founded
- EWTX 2017
- SSII N/A
- Country
- EWTX United States
- SSII India
- Employees
- EWTX N/A
- SSII N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- SSII
- Sector
- EWTX Health Care
- SSII
- Exchange
- EWTX Nasdaq
- SSII Nasdaq
- Market Cap
- EWTX 1.6B
- SSII 1.4B
- IPO Year
- EWTX 2021
- SSII N/A
- Fundamental
- Price
- EWTX $14.95
- SSII $6.67
- Analyst Decision
- EWTX Buy
- SSII
- Analyst Count
- EWTX 10
- SSII 0
- Target Price
- EWTX $37.90
- SSII N/A
- AVG Volume (30 Days)
- EWTX 957.0K
- SSII 63.3K
- Earning Date
- EWTX 11-06-2025
- SSII 11-14-2025
- Dividend Yield
- EWTX N/A
- SSII N/A
- EPS Growth
- EWTX N/A
- SSII N/A
- EPS
- EWTX N/A
- SSII N/A
- Revenue
- EWTX N/A
- SSII $27,623,624.00
- Revenue This Year
- EWTX N/A
- SSII N/A
- Revenue Next Year
- EWTX N/A
- SSII N/A
- P/E Ratio
- EWTX N/A
- SSII N/A
- Revenue Growth
- EWTX N/A
- SSII 134.89
- 52 Week Low
- EWTX $10.60
- SSII $2.48
- 52 Week High
- EWTX $38.12
- SSII $22.42
- Technical
- Relative Strength Index (RSI)
- EWTX 49.70
- SSII 54.09
- Support Level
- EWTX $14.85
- SSII $6.23
- Resistance Level
- EWTX $15.84
- SSII $7.74
- Average True Range (ATR)
- EWTX 1.08
- SSII 0.67
- MACD
- EWTX -0.06
- SSII 0.15
- Stochastic Oscillator
- EWTX 31.42
- SSII 59.85
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About SSII SS Innovations International Inc.
SS Innovations International Inc is a commercial-stage surgical robotics company focused on transforming patient lives by democratizing access to advanced surgical robotics technologies. The company designs, manufactures, and markets an advanced, next-generation, and affordable surgical robotic system called the SSi Mantra, and the instruments and accessories used with SSi Mantra to perform a wide range of soft-tissue, robotically assisted surgeries. The company earns the majority of its revenue from India.